Apogee, Sagimet overshoot IPO expectation as both biotechs land on Nasdaq

If the sight of two biotechs hopping onto the Nasdaq on the same day isn’t enough of a sign that the freezing IPO waters may be thawing, then the fact both companies have overshot expectations may help warm up sentiment further.